Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy
Brian Warnecke,Misako Nagasaka
DOI: https://doi.org/10.2147/dddt.s466217
IF: 4.3188
2024-12-06
Drug Design Development and Therapy
Abstract:Brian Warnecke, 1 Misako Nagasaka 1, 2 1 Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA; 2 Department of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan Correspondence: Misako Nagasaka, Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USA, Email One of the most common mutations seen in lung cancers are mutations in Kristen Rat Sarcoma Viral Oncogene Homolog (KRAS), observed in 25– 30% of patients with NSCLC. Mutations in KRAS result in oncogenesis via persistent activation of the MAPK/ERK pathways. Although once thought to be "undruggable", KRAS p.G12C inhibitors such as sotorasib and adagrasib have been developed. This paper focuses on adagrasib, the second KRAS p.G12C inhibitor to obtain regulatory approval by the FDA and describes the details on its study design, development and current place in therapy. Keywords: Kristen Rat Sarcoma Viral Oncogene Homolog, sotorasib, AMG510, MRTX849, KRYSTAL, CodeBreaK, brain penetration Oncogenic driver mutations are detected in approximately 60% of non-small cell lung cancers (NSCLC). 1 Next generation sequencing (NGS) enables the identification of mutations with therapeutic implications, allowing for the use of targeted agents. 2–4 The most common mutation, however, are mutations in Kristen Rat Sarcoma Viral Oncogene Homolog (KRAS) which are seen in approximately 25–30% of patients with NSCLC. 1,5 Notably, there is a vast heterogeneity within the subtypes of KRAS-mutated NSCLC, and prevalence rates can vary geographically. The most common KRAS mutation is the p.G12C mutation, characterized by a glycine-to-cysteine mutation at codon 12. This is estimated to be seen in 40% of patients with KRAS-mutated NSCLC. The next most common KRAS mutations are G12V (19%), and G12D (15%). 5,6 KRAS mutations have higher frequency in adenocarcinomas than squamous cell carcinomas, 37.2% vs 4.4%, respectively. 5 Patients who are current or former smokers are also more likely to harbor KRAS mutations compared to non-smokers, one study reporting 34% vs 6%, respectively. Within the smoking cohort, KRAS p.G12C is the most common mutation seen and observed in 41% of those patients. 7 The oncogenesis of KRAS-mutated NSCLC revolves around the MAPK/ERK biochemical cascade. KRAS is one of three isoforms within the RAS group of oncogenes. It is a GTPase protein located on the cell membrane and functions to directly interact with the downstream signaling MAPK/ERK pathways, which is vital for cell survival, growth, and differentiation. 8 In KRAS mutant cells, GTP-bound KRAS remains persistently active, triggering a downstream cascade of phosphorylation and kinase activation of MEK and ERK. ERK kinases translocate to the nucleus of the cell to aid in vital cell functions. In RAS-mutant human cancer cells, these proteins exhibit single amino-acid replacements primarily residing at G12 or Q61. Thus, these RAS-mutant cells remain GTP-bound, leading to persistently activated signaling of their downstream cascade allowing for oncogenesis. 9 Lung cancer is the main etiology of brain metastases, accounting for 40–50% of all brain metastases. 10 Up to 25–50% of patients with KRAS-mutated NSCLC are diagnosed with brain metastases. 11,12 The development of brain metastases in patients with KRAS-mutated NSCLC is associated with a worse overall survival (OS) and quality of life. CNS failures are seen more frequently when compared with patients without KRAS mutations. 11,13 KRAS mutations are not only seen in NSCLC. In addition, they can be observed in 90% of pancreatic cancers and 50% of colorectal cancers. 14,15 KRAS p.G12C mutations are also seen in approximately 3.2% of patients with colorectal cancer, 3.1% of patients with small bowel cancer, 3.3% of patients with appendiceal cancers, and 3.5% of patients with cancers of unknown primary. 16 Mutations in KRAS distinctly provide negative prognostic value for patients with gastrointestinal cancers too. Among patients diagnosed with metastatic colorectal cancer, KRAS mutations were correlated with inferior progression free survival (PFS) and OS, exhibiting a multivariate hazard ratio (HR) of 1.20 (95% confidence interval [CI] 1.02–1.42) and HR of 2.99 (95% CI 2.10–4.42), respectively. Specifically, in this cohort of patients, KRAS p.G12C mutations were associated with inferior OS in comparison to tumors without KRAS p.G12C mutations with an HR of 2.26 (95% CI 1.25–4.1). 15 As described above, the oncogenic potential KRAS mutations lie with its ability to constitutively acti -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal